New Clinical Data and Cutting-Edge Advances to Be Presented at the 2023 Oligonucleotide Therapeutics Society Meeting
SAN DIEGO, August 30, 2023 (Newswire.com) - This year's Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) will be held in Barcelona, Spain, from October 22-25. At the annual meeting, leaders and students from around the world present and discuss their discoveries over four days, and attendees engage in a cross-disciplinary exchange, fostering the development of ground-breaking new ideas.
OTS is an open, nonprofit forum to foster academic and industry-based research and development of oligonucleotide therapeutics, bringing together expertise from different angles to create synergies and bring the field to its full therapeutic potential.
The 2023 Oligo Meeting will provide in-depth information, covering a broad range of current topics in the field, and the keynote speaker, David Liu, Ph.D., of The Broad Institute, will speak about base editing and prime editing.
Engaging session topics include chemistry and delivery, DNA/RNA editing, information on current early and late-stage pre-clinical work, and the highly anticipated Clinical Session. A short talk session, which is new this year, consists of talks selected from submitted abstracts.
Two dynamic pre-conference sessions are being hosted this year. The Next Gen early career scientist session features up-and-comers who submitted abstracts for consideration for short talks. An educational session that includes a panel discussion will explore innovating and commercializing the next generation of oligonucleotide therapeutics.
The highly anticipated Clinical Session includes presentations by Jane Larkindale, PhD, of PepGen, on a Phase 1 healthy volunteer study of an enhanced delivery oligonucleotide to treat Duchenne Muscular Dystrophy, and Mike Flanagan, PhD, of Avidity Biosciences on developing antibody oligonucleotide conjugates for muscle disease. Mark O'Carroll of Arrowhead Pharmaceuticals will discuss clinical trial experience of inhaled administration of siRNA therapeutics, and Kenneth Newman, MD, of Ionis Pharmaceuticals, will speak about long-term safety and efficacy of ASO therapy to prekallikrein in patients with Hereditary Angioedema. Experts from Moderna Therapeutics and Alnylam Pharmaceuticals will also be speaking.
The final session features talks on late-breaking information. Abstracts can still be submitted for consideration by individuals or organizations by sending an email with the subject line: Late Breaking Talk - 2023 Barcelona. The committee is looking for talks showing exciting new clinical data in the field of oligo therapeutics, new pre-clinical data using oligo-based therapeutics, and new advances in delivery technologies or in CRISPR/mRNA/RNA editing.
The Society is honored to present society awards, including Lifetime Achievement Awards, to deserving individuals during the Annual Meeting. This year, attendees will hear from the 2022 and 2023 Lifetime Achievement Award winners: Sudhir Agrawal, MSc, Phil, and Cy Stein, MD, PhD.
OTS would also like to thank the sponsors and exhibitors for their support and participation. Over 30 companies, a record-breaking number, are scheduled to exhibit at this year's annual meeting.
Anyone interested or involved in oligonucleotide therapeutics is welcome to attend the OTS Annual Meeting, virtually or in person. Learn more and register at 2023oligomeeting.com.
Source: Oligonucleotide Therapeutics Society
